Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Brokerages

Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) has received an average rating of "Buy" from the five research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $42.50.

A number of research firms have weighed in on RPRX. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Monday, May 12th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Morgan Stanley began coverage on Royalty Pharma in a report on Friday. They set an "overweight" rating and a $51.00 price objective on the stock.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors have recently added to or reduced their stakes in the business. Applied Finance Capital Management LLC boosted its holdings in Royalty Pharma by 3.0% in the 1st quarter. Applied Finance Capital Management LLC now owns 11,265 shares of the biopharmaceutical company's stock valued at $351,000 after purchasing an additional 329 shares in the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in Royalty Pharma by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock worth $1,238,000 after acquiring an additional 349 shares during the period. Keene & Associates Inc. grew its stake in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock worth $495,000 after acquiring an additional 370 shares during the period. National Bank of Canada FI grew its stake in shares of Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 371 shares during the period. Finally, Blue Trust Inc. grew its stake in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 376 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Trading Up 2.7%

RPRX opened at $34.02 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The business's 50 day moving average price is $32.39 and its 200 day moving average price is $29.97. Royalty Pharma has a one year low of $24.05 and a one year high of $34.20. The stock has a market capitalization of $19.61 billion, a PE ratio of 23.46, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The company had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities research analysts expect that Royalty Pharma will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma's dividend payout ratio is currently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.